Skip to main content

Table 1 Clinical characteristics of 341 patients

From: Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Characteristics SUA after two cycles of IC > 327 μmol/L (%) SUA after two cycles of IC ≤ 327 μmol/L (%) PR/CR (%) SD/PD (%)
Total 167 (49.0%) 174 (51.0%) 236 (69.2%) 105 (30.8%)
Gender
 Female 130 (38.1%) 101 (29.6%) 155 (45.5%) 76 (22.3%)
 Male 37 (10.9%) 73 (21.4%) 81 (23.7%) 29 (8.5%)
Age (years)
  ≤ 50 92 (27.0%) 97 (28.4%) 130 (38.1%) 59 (17.3%)
  > 50 75 (22.0%) 77 (22.6%) 106 (31.1%) 46 (13.5%)
Pathological type
 WHO I 0 (0) 2 (0.6%) 0 (0) 2 (0.6%)
 WHO II 9 (2.6%) 9 (2.6%) 12 (3.5%) 6 (1.8%)
 WHO III 158 (46.3%) 163 (47.8%) 224 (65.7%) 97 (28.4%)
T stage
 T1 24 (7.0%) 17 (5.0%) 28 (8.2%) 13 (3.8%)
 T2 32 (9.4%) 38 (11.1%) 52 (15.2%) 18 (5.3%)
 T3 65 (19.1%) 72 (21.1%) 99 (29.0%) 38 (11.1%)
 T4 46 (13.5%) 47 (13.8%) 57 (16.7%) 36 (10.6%)
N stage
 N0 11 (3.2%) 7 (2.1%) 11 (3.2%) 7 (2.1%)
 N1 49 (14.4%) 68 (19.9%) 80 (23.5%) 37 (10.9%)
 N2 87 (25.5%) 79 (23.2%) 115 (33.7%) 51 (15.0%)
 N3 20 (5.9%) 20 (5.9%) 30 (8.8%) 10 (2.9%)
Chemotherapy cycles
  ≤ 3 31 (9.1%) 31 (9.1%) 41 (12.0%) 21 (6.2%)
  > 3 136 (39.9%) 143 (41.9%) 195 (57.2%) 84 (24.6%)
  1. Abbreviations: CR complete response, IC induction chemotherapy, PD disease progression, PR partial response, SD stable disease, SUA serum uric acid